Glycyx

Glycyx has a breakthrough cancer therapy that blocks a fundamental injury response pathway turning cold tumors hot and enabling immune infiltration of the TME.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location San Francisco, CA 94121, USA
  • Currency USD
  • Founded January 2021
  • Employees 5
  • Incorporation Type C-corp
  • Website glycyxtherapeutics.com

Company Summary

Glycyx has developed a minimally-toxic cancer therapy that can turn immunologically cold tumors hot. Our lead candidate, axelopran, enables immune infiltration of the tumor microenvironment (TME) reducing tumor growth and preventing T-cell exhaustion.

Team

Advisors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free